CollPlant, an Israeli biotech company recently announced the promising results of a clinical trial of their bioengineered collagen product (combined with Platelet-Rich Plasma Injection Therapy) in the treatment of Tennis Elbow.
The clinical study, which was concluded in August of 2016, was published Nov 26, 2018 in the Journal of Shoulder and Elbow Surgery.
First Clinical Experience With A New Injectable Recombinant Human Collagen Scaffold Combined With Autologous Platelet-Rich Plasma For The Treatment Of Lateral Epicondylar Tendinopathy (Tennis Elbow)New Clinical Study Of Bio-Engineered Collagen For Treating Tennis Elbow was originally published on: https://tenniselbowclassroom.com (Read the full article there.)
"Based on positive outcomes from preclinical trials, this study is the first clinical trial of STR/PRP on tendinopathy."
"The study enrolled 40 patients. No systemic or local severe adverse events were reported. Clinical evaluation revealed an improvement in the mean Patient-Rated Tennis Elbow Evaluation score from 64.8 before treatment and showed a 59% reduction at 6 months."
Farkash, Uri et al; J. of Shoulder and Elbow Surgery; doi.org/10.1016/j.jse.2018.09.007
- 28% increase in grip strength,
- 59% improvement of Patient-Rated Tennis Elbow Evaluation score,
- 68% showed improvements in tendon appearance via sonographic imaging
https://www.jshoulderelbow.org/article/S1058-2746(18)30697-9/fulltext
No comments:
Post a Comment